OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
BIOC$28.4855

GlaxoSmithKline SAE

PharmaceuticalsVerified

The company's capital structure is characterized by a relatively low debt-to-equity ratio of 0.08, indicating a conservative leverage position. However, the negative operating cash flow of -187,089,650 and free cash flow of -29,978,620 suggest liquidity constraints. The price-to-book ratio of 1.26 and price-to-tangible-book ratio of 1.26 indicate that the market values the company slightly above its book value. Profitability metrics show a concerning trend, with a negative return on equity of -0.0048 and a negative return on assets of -0.0023. These figures fall significantly below the typical performance of the pharmaceutical industry, which is generally characterized by high gross margins and strong returns on investment. The company's operating income of 69,376,010 is a fraction of its revenue of 713,808,740, indicating a low operating margin. The company's revenue concentration is not explicitly detailed in the available data, but the absence of segment-specific revenue breakdowns suggests a lack of transparency in geographic or product diversification. This could imply a higher risk of revenue volatility if the company is overly dependent on a single market or product line. The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the outlook. The negative net income of -8,990,370 and the negative operating cash flow suggest a challenging operating environment. The capital expenditure of -33,714,880 indicates ongoing investment, but the negative free cash flow implies that these investments are not yet generating positive returns. The risk assessment highlights a medium liquidity risk, primarily due to the negative net cash position after accounting for total debt. The dilution risk is assessed as low, but the negative net income and operating cash flow could pressure the company to raise additional capital, potentially leading to share dilution. The adjustments applied in the valuation suggest that the market is factoring in these financial challenges. Recent events and filings are not detailed in the provided data, but the negative net income and operating cash flow suggest that the company may have faced operational or market challenges. The absence of specific recent events or transcripts limits the ability to assess the company's current strategic direction or external pressures.

30-day price · BIOC+17.62 (+29.9%)
Low$58.46High$79.99Close$76.52As of14 May, 00:00 UTC
Profile
CompanyGlaxoSmithKline SAE
TickerBIOC.CA
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. GlaxoSmithKline SAE is a pharmaceutical company that develops, manufactures, and markets prescription and over-the-counter medicines, vaccines, and consumer healthcare products.

Classification. The company is classified under the Healthcare economic sector, Pharmaceuticals & Medical Research business sector, and the Pharmaceuticals industry with a confidence level of 0.92.

The company's capital structure is characterized by a relatively low debt-to-equity ratio of 0.08, indicating a conservative leverage position. However, the negative operating cash flow of -187,089,650 and free cash flow of -29,978,620 suggest liquidity constraints. The price-to-book ratio of 1.26 and price-to-tangible-book ratio of 1.26 indicate that the market values the company slightly above its book value. Profitability metrics show a concerning trend, with a negative return on equity of -0.0048 and a negative return on assets of -0.0023. These figures fall significantly below the typical performance of the pharmaceutical industry, which is generally characterized by high gross margins and strong returns on investment. The company's operating income of 69,376,010 is a fraction of its revenue of 713,808,740, indicating a low operating margin. The company's revenue concentration is not explicitly detailed in the available data, but the absence of segment-specific revenue breakdowns suggests a lack of transparency in geographic or product diversification. This could imply a higher risk of revenue volatility if the company is overly dependent on a single market or product line. The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the outlook. The negative net income of -8,990,370 and the negative operating cash flow suggest a challenging operating environment. The capital expenditure of -33,714,880 indicates ongoing investment, but the negative free cash flow implies that these investments are not yet generating positive returns. The risk assessment highlights a medium liquidity risk, primarily due to the negative net cash position after accounting for total debt. The dilution risk is assessed as low, but the negative net income and operating cash flow could pressure the company to raise additional capital, potentially leading to share dilution. The adjustments applied in the valuation suggest that the market is factoring in these financial challenges. Recent events and filings are not detailed in the provided data, but the negative net income and operating cash flow suggest that the company may have faced operational or market challenges. The absence of specific recent events or transcripts limits the ability to assess the company's current strategic direction or external pressures.
Key takeaways
  • The company has a low debt-to-equity ratio but faces liquidity constraints due to negative operating and free cash flows.
  • Profitability metrics are negative, indicating a significant underperformance relative to the pharmaceutical industry.
  • The company's revenue concentration and lack of segment-specific data suggest potential exposure to market volatility.
  • Growth prospects are uncertain, with no clear revenue growth projections and ongoing capital expenditures that have not yet generated positive returns.
  • The risk assessment indicates a medium liquidity risk and a low dilution risk, but the financial challenges could lead to capital-raising activities.
  • --
  • # RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyEGP
Revenue$713.8M
Gross profit$326.4M
Operating income$69.4M
Net income-$9.0M
R&D
SG&A
D&A
SBC
Operating cash flow-$187.1M
CapEx-$33.7M
Free cash flow-$30.0M
Total assets$3.97B
Total liabilities$2.09B
Total equity$1.88B
Cash & equivalents
Long-term debt$152.2M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$1.01B$2.5M$154.6M-$52.6M
FY-3$1.82B-$64.0M$735.4M-$223.8M
FY-2$2.24B$285.3M$60.5M-$100.4M
FY-1$2.99B$418.7M$174.0M$33.6M
FY0$3.73B$253.1M$213.2M$83.3M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$2.42B$1.36B
FY-3$3.19B$1.73B
FY-2$3.56B$1.96B
FY-1$3.65B$1.99B$75.5M
FY0$4.50B$2.22B$479.7M
PeriodOCFCapExFCFSBC
FY-4$192.2M-$35.8M-$52.6M
FY-3$1.04B-$48.8M-$223.8M
FY-2$302.3M-$77.1M-$100.4M
FY-1-$404.1M-$124.3M$33.6M
FY0$240.8M-$177.3M$83.3M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$713.8M$69.4M-$9.0M-$30.0M
FQ-6$642.4M$132.9M$101.5M$92.8M
FQ-5$787.1M$81.9M$13.3M-$59.3M
FQ-4$847.5M$134.5M$68.2M$30.1M
FQ-3$993.9M$114.8M$59.1M$65.7M
FQ-2$891.0M-$11.5M$5.9M-$12.8M
FQ-1$1.01B-$77.7M-$34.8M-$66.3M
FQ0$837.5M$227.5M$183.0M$110.3M
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$3.97B$1.88B
FQ-6$3.74B$1.91B
FQ-5$3.71B$1.93B
FQ-4$3.65B$1.99B$75.5M
FQ-3$4.61B$2.11B$225.5M
FQ-2$4.87B$2.01B$317.2M
FQ-1$4.53B$2.03B$342.8M
FQ0$4.50B$2.22B$479.7M
PeriodOCFCapExFCFSBC
FQ-7-$187.1M-$33.7M-$30.0M
FQ-6-$371.9M-$48.5M$92.8M
FQ-5-$216.5M-$71.6M-$59.3M
FQ-4-$404.1M-$124.3M$30.1M
FQ-3$108.4M-$7.4M$65.7M
FQ-2$95.8M-$40.6M-$12.8M
FQ-1$129.8M-$87.5M-$66.3M
FQ0$240.8M-$177.3M$110.3M
Valuation
Market price$28.48
Market cap$2.38B
Enterprise value$2.53B
P/E
Reported non-GAAP P/E
EV/Revenue3.5
EV/Op income36.5
EV/OCF
P/B1.3
P/Tangible book1.3
Tangible book$1.88B
Net cash-$152.2M
Current ratio1.6
Debt/Equity0.1
ROA-0.2%
ROE-0.5%
Cash conversion20.8%
CapEx/Revenue-4.7%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals · cohort 779 companies
MetricBIOCActivity
Op margin9.7%7.7% medp25 -2.4% · p75 15.5%above median
Net margin-1.3%5.9% medp25 -3.8% · p75 12.8%below median
Gross margin45.7%45.5% medp25 31.1% · p75 62.9%above median
R&D / revenue529.2% medp25 465.2% · p75 593.2%
CapEx / revenue-4.7%-7.0% medp25 -14.9% · p75 -3.2%above median
Debt / equity8.0%25.0% medp25 3.8% · p75 63.3%below median
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-10 10:45 UTC#95f17976
Market quoteclose EGP 28.48 · shares 0.08B diluted
no public URL
2026-05-10 10:45 UTC#91b1e068
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 12:24 UTCJob: 65669b3a